西格列汀联合胰岛素强化治疗对初诊2型糖尿病疗效观察  

Effect of Intensive Insulin Treatment Combined with Sitagliptin on Patients with Newly Diagnosed Type 2 Diabetic

作　　者：李绪娴[1] 

机构地区：[1]惠州市第三人民医院,广东惠州516001

出　　处：《药物流行病学杂志》2015年第6期332-334,共3页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:评价西格列汀联合胰岛素强化治疗初诊2型糖尿病的临床疗效。方法:初诊2型糖尿病患者120例随机分成两组,A组予胰岛素强化治疗,B组在A组基础上加用西格列汀片100 mg,po qd。治疗12周后比较两组患者的血糖、血脂各项指标及药品不良反应。结果:治疗后,两组患者的空腹血糖(FPG)、餐后2 h血糖(2h FPG)、糖化血红蛋白(Hb A1c)、总胆固醇(TG)、低密度脂蛋白(LDL)等指标均较治疗前显著下降(P<0.05),高密度脂蛋白(HDL)较治疗前明显升高(P<0.05),且B组FPG、2h FPG、Hb A1c、TG比A组下降更明显(P<0.05)。两组患者胰岛β细胞功能、稳态模型胰岛素抵抗指数(HOMA-IR)均较前明显改善(P<0.05),且B组胰岛β细胞功能的改善优于A组(P<0.05)。治疗过程中B组低血糖频率显著低于A组(P<0.05)。结论:西格列汀联合胰岛素强化治疗可有效控制初诊2型糖尿病患者的血糖,显著减少低血糖事件的发生,改善患者的胰岛β细胞功能,并具有一定的降血脂作用。Objective： To evaluate the effect of intensive insulin treatment combined with sitagliptin on patients with newly diagnosed type 2 diabetic. Methods： 120 newly diagnosed type 2 diabetic patients were randomly divided into two groups, group Awas treated with intensive insulin alone, group B was treated with intensive insulin combined with sita- gliptin. The FPG, 2hFPG, HbAlc, TG, TC, LDL, HDL, HOMA-β, HOMA-IR and frequency of hypoglycaemia of two groups were compared after 12 weeks treatment. Results： After treatment,the FPG, 2hFPG, HbAlc, TG, LDL and HO- MA-IR of the two groups were all decreased significantly than betore（ P 〈 0.05 ）, while the HDL and HOMA-β were in- creased significantly （ P 〈 0.05 ） , and the TC and LDL showed no obvious changes （ P 〉 0.05 ）. After treatment, the FPG, 2hFPG, HbAI c and TG of group B were all lower than those of group A significantly （ P 〈 0.05 ）, while HOMA-β was high- er than group A （ P 〈 0.05）, and LDL, HDL, TC and HOMA-IR showed no obvious differences （P 〉 0.05）. The fre- quency of hypoglycaemia of group B was lower than group A significantly （ P 〈0.05 ）. Conclusion：The combination of in- tensive insulin treatment with sitagliptin can not only control the blood glucose level, but also decrease the frequency of hy- poglycaemia, improve the islet β-cell function, and play a certain role in reducing blood lipid.

关 键 词：胰岛素强化治疗 西格列汀 初诊2型糖尿病 

分 类 号：R977.15[医药卫生—药品]